Second-line Therapy for advanced non-small-cell lung cancer (Q36718606)

15 August 2017

1 reference

title

Second-line Therapy for advanced non-small-cell lung cancer (English)

1 reference

15 August 2017

Christine L Hann

1

1 reference

15 August 2017

Julie R Brahmer

series ordinal

2

1 reference

15 August 2017

publication date

1 July 2006

1 reference

15 August 2017

published in

Current Oncology Reports

1 reference

15 August 2017

volume

8

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

243-247

1 reference

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

15 August 2017

cites work

1 reference

12 December 2020

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

1 reference

12 December 2020

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

12 December 2020

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

1 reference

12 December 2020

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

1 reference

12 December 2020

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

12 December 2020

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

12 December 2020

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

1 reference

12 December 2020

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel

1 reference

12 December 2020

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer

1 reference

12 December 2020

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

12 December 2020

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

12 December 2020

Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology

1 reference

12 December 2020

Multidisciplinary management of lung cancer

1 reference

12 December 2020

Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial

1 reference

12 December 2020

Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.

1 reference

12 December 2020

Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.

1 reference

12 December 2020

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

1 reference

12 December 2020

LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes

1 reference

12 December 2020

ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study

1 reference

12 December 2020

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

ZD6474--clinical experience to date

1 reference

12 December 2020

Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial

1 reference

12 December 2020

10.1007/S11912-006-0027-3

Identifiers

DOI

1 reference

15 August 2017

1 reference